DaShenLin Pharmaceutical Group Co AAQS
The The AAQS of DaShenLin Pharmaceutical Group Co (603233.SS) as of Oct 24, 2026 is 10. In the previous year, The AAQS was 10.00 — a change of 0.00% (lower).
Get this data via API
Financial Data API
AAQS
10
YoY
0.00%
Last updated:
DaShenLin Pharmaceutical Group Co has a current AAQS of 10.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock DaShenLin Pharmaceutical Group Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
A high AAQS can be seen as a positive indicator that the company is developing successfully.
Investors can assume that the company is on a good path to generate profits.
On the other hand, it is important to consider the AAQS of the stock DaShenLin Pharmaceutical Group Co in comparison to the profits generated and other companies in the same industry. A high AAQS is not an absolute guarantee for a positive future. Only in this way can one get a complete picture of the company's performance.
In order to better assess the company's development, it is important to consider the AAQS in comparison to other companies in the same industry. In general, investors should always consider the AAQS of a company in connection with other fundamentals such as profit, EBIT, cash flow, and others in order to make an informed investment decision.
The DaShenLin Pharmaceutical Group Co AAQS history
3 Years
10 Years
25 Years
Max
AAQS
Date
AAQS
Jan 1, 2018
10.00 CNY
Jan 1, 2019
10.00 CNY
Jan 1, 2020
10.00 CNY
Jan 1, 2021
10.00 CNY
Jan 1, 2022
10.00 CNY
Jan 1, 2023
10.00 CNY
Jan 1, 2024
10.00 CNY
Jan 1, 2025
10.00 CNY
| YEAR | AAQS | YoY |
|---|---|---|
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | 0.00% | |
| 10 | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
DaShenLin Pharmaceutical Group Co Stock analysis
What does DaShenLin Pharmaceutical Group Co do? DaShenLin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.
Frequently Asked Questions about DaShenLin Pharmaceutical Group Co stock
The AAQS of DaShenLin Pharmaceutical Group Co is 10 in 2025.
On Eulerpool you can find the complete historical development of The AAQS DaShenLin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.
The AAQS is a key figure developed by AlleAktien.
The AAQS is a key figure developed by AlleAktien.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — DaShenLin Pharmaceutical Group Co
All Key Metrics — DaShenLin Pharmaceutical Group Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth